Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Biocon Ltd.'s net profit margin of 8.7% in FY2025 reflects thin profitability, with operating margin at 16.3% and gross margin at 68.4%.
In FY 2025, Biocon Ltd. posted a gross margin of 68.4%, an operating margin of 16.3%, a net margin of 8.7%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Biocon Ltd.'s revenue grew 5.4% to 164.70B and net profit grew 10.1% to 14.29B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Biocon Ltd.'s revenue grew by 5.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Biocon Ltd.'s ROE of 5.2% in FY2025 indicates below-average shareholder returns.
In FY 2025, Biocon Ltd. reported an ROE of 5.2%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Biocon Ltd.'s FCF/NI ratio of 1.35x in FY2025 indicates high-quality, cash-backed earnings.
In FY 2025, Biocon Ltd.'s free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Biocon Ltd.'s OCF/NI ratio of 2.84x in FY2025 indicates strong cash collection and working capital efficiency.
In FY 2025, Biocon Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Biocon Ltd.'s current ratio of 1.14x in FY2025 indicates adequate but thin liquidity.
In FY 2025, Biocon Ltd. reported a current ratio of 1.14. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Biocon Ltd.'s interest coverage ratio of 3.0x in FY2025 indicates acceptable but limited debt servicing headroom.
In FY 2025, Biocon Ltd. reported an interest coverage ratio of 3.0x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Biocon Ltd.'s debt-to-equity ratio of 0.66x in FY2025 reflects a balanced capital structure with moderate leverage.
In FY 2025, Biocon Ltd. reported a debt-to-equity ratio of 0.66. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Biocon Ltd.'s debt increased 12.8% YoY in FY2025 — debt levels are increasing.
In FY 2025, Biocon Ltd.'s total debt increased by 12.8% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Biocon Ltd.'s diluted shares increased 0.1% YoY in FY2025 — share dilution.
Over 2 years (FY2024–FY2025), diluted shares increased 0.1% from 1.20B to 1.20B, indicating cumulative dilution.
In FY 2025, Biocon Ltd.'s diluted shares increased by 0.1% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025